Informed Consent for Systemic Chemotherapy Administration

Section 1info grid
Section 2text block
Section 3text block
Section 4list block
Section 5list block
Section 6text block
Section 7text block
Section 8text block
Section 9text block
Section 10text block
Section 11text block
Section 12text block
Section 13signature block

Informed Consent for Systemic Chemotherapy Administration

Patient and Treatment Information

Nature and Purpose of Treatment

Chemotherapy uses cytotoxic (cell-killing) drugs that interfere with cancer cell division, DNA replication, or specific cellular survival mechanisms. Drugs are administered via intravenous infusion through a peripheral vein, central venous catheter (CVC), peripherally inserted central catheter (PICC), or implanted port, on a scheduled cycle basis (typically every 2 to 4 weeks, allowing normal tissue recovery between cycles). Oral chemotherapy is also used in certain regimens. The specific drugs, doses, and schedule that constitute the prescribed regimen were selected based on the established evidence for the cancer type, stage, and your individual patient characteristics (organ function, performance status, prior therapy). Chemotherapy treats cancer by one or more of the following mechanisms: alkylating the DNA of cancer cells (e.g. cyclophosphamide, cisplatin), inhibiting DNA synthesis (e.g. 5-fluorouracil, gemcitabine), stabilizing microtubules to prevent cell division (e.g. paclitaxel, docetaxel), or inducing programmed cell death (apoptosis). Because chemotherapy drugs have limited specificity for cancer cells versus rapidly dividing normal cells (hair follicles, bone marrow, gastrointestinal mucosa), they produce characteristic side effect profiles.

Neutropenic Fever: Emergency Protocol — Read Carefully

Chemotherapy suppresses bone marrow production of white blood cells (neutrophils), creating a period of immunosuppression called the nadir (typically 10 to 14 days after each cycle when neutrophil counts are lowest). During this period, even minor infections can become rapidly life-threatening. MANDATORY: Measure your temperature at least twice daily at home during the nadir period. If you develop a temperature at or above 38.0 degrees Celsius (100.4 degrees Fahrenheit) at any time during treatment, you must call the oncology emergency line immediately and proceed to the emergency department without delay. Do not wait until morning. Neutropenic fever is a medical emergency that requires urgent intravenous broad-spectrum antibiotics. The 24-hour oncology emergency contact is: [Insert Oncology Emergency Hotline Number Here].

Material Risks and Side Effects

Myelosuppression (bone marrow suppression): reduced neutrophils (risk of serious infection), reduced red blood cells / anaemia (fatigue, breathlessness, need for transfusion), and reduced platelets / thrombocytopenia (risk of bleeding). Complete blood count is monitored before each cycle and may require dose reduction, treatment delay, or growth factor support (G-CSF).
Nausea and vomiting: managed with modern prophylactic antiemetic regimens (5-HT3 antagonists, NK1 antagonists, dexamethasone). Most patients tolerate contemporary regimens well, but breakthrough nausea requiring rescue antiemetics occurs in 20 to 30 percent.
Alopecia (hair loss): temporary and reversible with most standard regimens; permanent alopecia is associated with busulfan and rare with other agents. Hair typically regrows 2 to 4 months after completing chemotherapy.
Peripheral neuropathy: numbness, tingling, and pain in the hands and feet, particularly associated with taxanes (paclitaxel, docetaxel) and platinum compounds (cisplatin, oxaliplatin). May be dose-limiting; partial to complete recovery occurs in most patients over months to years, but permanent neuropathy is possible in 10 to 20 percent exposed to high cumulative doses.
Cardiotoxicity: anthracyclines (doxorubicin, epirubicin) are associated with dose-dependent cardiomyopathy and heart failure. Cumulative lifetime dose limits apply. Cardiac function (echocardiogram) is monitored before and during treatment. Trastuzumab and other targeted agents may also cause reversible cardiac dysfunction.
Nephrotoxicity: cisplatin is a major nephrotoxin; adequate IV hydration and amifostine pre-treatment reduce but do not eliminate renal injury. Creatinine and GFR are monitored throughout treatment.
Hepatotoxicity: many chemotherapy agents cause transient liver enzyme elevation; severe hepatotoxicity may require dose reduction or drug substitution.
Fertility impairment: alkylating agents (cyclophosphamide, melphalan) and certain other chemotherapy drugs may cause temporary or permanent gonadal damage, leading to infertility and premature menopause in women, and azoospermia in men. Fertility preservation consultation (sperm banking, oocyte or embryo cryopreservation) should be completed before chemotherapy if the patient has not yet completed their family.
Secondary malignancy: chemotherapy, particularly with alkylating agents and topoisomerase II inhibitors, carries a small but measurable lifetime risk (approximately 0.5 to 1 percent) of inducing treatment-related myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).
Mucositis: painful inflammation and ulceration of the gastrointestinal mucosa from mouth to anus; severity varies by regimen; managed with mouth rinses, topical analgesics, and nutritional support.
Extravasation: if vesicant chemotherapy drugs leak out of the vein during infusion, severe tissue necrosis may result at the injection site. Close monitoring during infusion and use of a central venous access device minimize this risk.

Alternatives to the Proposed Chemotherapy Regimen

Alternative chemotherapy regimens: other evidence-based drug combinations may be available for this cancer type; the risks and benefits of each were considered in selecting this regimen based on the clinical scenario.
Targeted therapy or immunotherapy: depending on tumour molecular profile (e.g. HER2, PD-L1, EGFR, ALK, BRCA status), targeted oral agents or immune checkpoint inhibitors may be appropriate as alternatives or in combination.
Participation in a clinical trial: enrolment in an investigational study may provide access to novel agents; the oncology team can provide information on applicable open trials.
Best supportive care (palliative intent only): for patients declining active treatment, all efforts will be directed toward symptom control, pain management, and quality of life optimization through the palliative care team.

Expected Benefits

The expected benefit of chemotherapy depends on the treatment intent specified above. With curative or adjuvant intent, the goal is to eliminate residual cancer cells, reduce the risk of recurrence, and achieve long-term disease-free or overall survival. With neoadjuvant intent, the goal is to reduce tumour size before surgery or radiation to enable less extensive resection. With palliative intent, the goal is to control disease progression, relieve symptoms, and improve quality of life. The specific expected response rates, survival benefits, and probability of achieving the treatment goals based on your individual clinical scenario have been discussed with you by your oncologist.

Fertility Preservation Consultation Requirement

Chemotherapy, particularly with alkylating agents, can cause temporary or permanent infertility. If you are of reproductive age and have not completed your family, your oncology team is required to discuss fertility preservation options with you before treatment begins. Options include sperm banking for male patients and oocyte or embryo cryopreservation for female patients. A referral to a reproductive medicine specialist can be arranged urgently if required. Fertility preservation procedures may add a 2 to 4 week delay before chemotherapy initiation, which must be discussed with your oncologist in the context of clinical urgency.

Right to Refuse or Withdraw Consent

You have the right to refuse chemotherapy or withdraw your consent at any time, including mid-treatment, without penalty or adverse effect on your access to supportive and palliative care. Your oncology team will continue to support you and provide best supportive care if you choose not to proceed with or to discontinue treatment.

Questions and Understanding Confirmation

I have received and understood the neutropenic fever emergency protocol and the 24-hour oncology emergency contact number. I understand the mandatory blood count monitoring schedule before each cycle. I have been advised about fertility preservation and my decision regarding this is documented separately. All my questions have been answered to my satisfaction.

Language Access and Interpreter Services

If English is not your primary language or if you require assistance communicating, a qualified medical interpreter is available at no cost. Please notify your oncology care team before signing this document.

Copy of Consent Acknowledgment

I acknowledge that I have been offered a signed copy of this informed consent form for my own records.

Patient Authorization

I have been informed of the chemotherapy regimen, its intended purpose, the material side effects listed above, and the absolute obligation to report fever of 38.0 degrees Celsius or above immediately. I have been advised regarding fertility preservation options. I consent to receive the proposed chemotherapy regimen and agree to attend all scheduled clinic visits and blood count checks.

Signatures and Verification

Patient / LAR Signature
Oncologist Signature
Witness Signature
Date and Time
Document ID: CC-PENDING
CONSENTCOLLECT